{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:24:18Z","timestamp":1783225458522,"version":"3.54.6"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation (NRF) of Korea","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health and Welfare of Korea"},{"name":"SNUBH Research Fund","award":["14-2020-0003"],"award-info":[{"award-number":["14-2020-0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Homologous recombination deficiency (HRD) stands as a clinical indicator for discerning responsive outcomes to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors. One of the conventional approaches to HRD prognostication has generally centered on identifying deleterious mutations within the <jats:italic>BRCA1\/2<\/jats:italic> genes, along with quantifying the genomic scars, such as Genomic Instability Score (GIS) estimation with scarHRD. However, the scarHRD method has limitations in scenarios involving tumors bereft of corresponding germline data. Although several RNA-seq-based HRD prediction algorithms have been developed, they mainly support cohort-wise classification, thereby yielding HRD status without furnishing an analogous quantitative metric akin to scarHRD. This study introduces the expHRD method, which operates as a novel transcriptome-based framework tailored to n-of-1-style HRD scoring.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prediction model has been established using the elastic net regression method in the Cancer Genome Atlas (TCGA) pan-cancer training set. The bootstrap technique derived the HRD geneset for applying the expHRD calculation. The expHRD demonstrated a notable correlation with scarHRD and superior performance in predicting HRD-high samples. We also performed intra- and extra-cohort evaluations for clinical feasibility in the TCGA-OV and the Genomic Data Commons (GDC) ovarian cancer cohort, respectively. The innovative web service designed for ease of use is poised to extend the realms of HRD prediction across diverse malignancies, with ovarian cancer standing as an emblematic example.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our novel approach leverages the transcriptome data, enabling the prediction of HRD status with remarkable precision. This innovative method addresses the challenges associated with limited available data, opening new avenues for utilizing transcriptomics to inform clinical decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-024-05854-y","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:02:31Z","timestamp":1720778551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["expHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Jae Jun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ju","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si On","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanguk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ku","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"1","key":"5854_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6(1):254.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"5854_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/em.22087","volume":"58","author":"N Chatterjee","year":"2017","unstructured":"Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235\u201363.","journal-title":"Environ Mol Mutagen"},{"issue":"3","key":"5854_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/85798","volume":"27","author":"KK Khanna","year":"2001","unstructured":"Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247\u201354.","journal-title":"Nat Genet"},{"issue":"10","key":"5854_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.dnarep.2008.06.018","volume":"7","author":"Z Mao","year":"2008","unstructured":"Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst). 2008;7(10):1765\u201371.","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"5854_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/cr.2007.111","volume":"18","author":"M Shrivastav","year":"2008","unstructured":"Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18(1):134\u201347.","journal-title":"Cell Res"},{"issue":"1","key":"5854_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/cr.2008.1","volume":"18","author":"X Li","year":"2008","unstructured":"Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18(1):99\u2013113.","journal-title":"Cell Res"},{"issue":"12","key":"5854_CR7","doi-asserted-by":"publisher","first-page":"e2200060","DOI":"10.1002\/adbi.202200060","volume":"6","author":"JJ Lee","year":"2022","unstructured":"Lee JJ, Kang HJ, Kim SS, Charton C, Kim J, Lee JK. Unraveling the transcriptomic signatures of homologous recombination deficiency in ovarian cancers. Adv Biol (Weinh). 2022;6(12):e2200060.","journal-title":"Adv Biol (Weinh)"},{"issue":"2","key":"5854_CR8","first-page":"75","volume":"2","author":"AJ Bishop","year":"2002","unstructured":"Bishop AJ, Schiestl RH. Homologous recombination and its role in carcinogenesis. J Biomed Biotechnol. 2002;2(2):75\u201385.","journal-title":"J Biomed Biotechnol"},{"key":"5854_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19406-4","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, Martens JWM, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/s41467-020-19406-4.","journal-title":"Nat Commun"},{"key":"5854_CR10","doi-asserted-by":"publisher","first-page":"880643","DOI":"10.3389\/fonc.2022.880643","volume":"12","author":"N Mekonnen","year":"2022","unstructured":"Mekonnen N, Yang H, Shin YK. Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors. Front Oncol. 2022;12:880643.","journal-title":"Front Oncol"},{"key":"5854_CR11","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"5854_CR12","doi-asserted-by":"publisher","first-page":"101012","DOI":"10.1016\/j.tranon.2021.101012","volume":"14","author":"DC Janysek","year":"2021","unstructured":"Janysek DC, Kim J, Duijf PHG, Dray E. Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers. Transl Oncol. 2021;14(3):101012.","journal-title":"Transl Oncol"},{"issue":"3","key":"5854_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255\u201382.","journal-title":"Target Oncol"},{"issue":"26","key":"5854_CR14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"6","key":"5854_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"25","key":"5854_CR16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"key":"5854_CR17","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","volume":"9","author":"N Li","year":"2023","unstructured":"Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, Zheng H, Liu J, Wu X, Wang L, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9:1230.","journal-title":"JAMA Oncol"},{"issue":"1","key":"5854_CR18","doi-asserted-by":"publisher","first-page":"8899","DOI":"10.1038\/s41598-023-35092-w","volume":"13","author":"Z Shi","year":"2023","unstructured":"Shi Z, Chen B, Han X, Gu W, Liang S, Wu L. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types. Sci Rep. 2023;13(1):8899.","journal-title":"Sci Rep"},{"issue":"1","key":"5854_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-019-5950-4","volume":"19","author":"OA Zayas-Villanueva","year":"2019","unstructured":"Zayas-Villanueva OA, Campos-Acevedo LD, Lugo-Trampe JJ, Hernandez-Barajas D, Gonzalez-Guerrero JF, Noriega-Iriondo MF, Ramirez-Sanchez IA, Martinez-de-Villarreal LE. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study. BMC Cancer. 2019;19(1):722.","journal-title":"BMC Cancer"},{"issue":"7353","key":"5854_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"3","key":"5854_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/bcr3670","volume":"16","author":"JA Watkins","year":"2014","unstructured":"Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16(3):211.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"5854_CR22","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.esmoop.2021.100144","volume":"6","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: Do we need it? ESMO Open. 2021;6(3):100144.","journal-title":"ESMO Open"},{"key":"5854_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, Birkbak NJ, Eklund AC, Syed A, Szallasi Z. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4:16.","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"5854_CR24","doi-asserted-by":"publisher","first-page":"e113169","DOI":"10.1371\/journal.pone.0113169","volume":"9","author":"S Zhang","year":"2014","unstructured":"Zhang S, Yuan Y, Hao D. A genomic instability score in discriminating nonequivalent outcomes of BRCA1\/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS ONE. 2014;9(12):e113169.","journal-title":"PLoS ONE"},{"key":"5854_CR25","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/ncomms4361","volume":"5","author":"G Peng","year":"2014","unstructured":"Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun. 2014;5:3361.","journal-title":"Nat Commun"},{"issue":"1","key":"5854_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12885-022-09669-z","volume":"22","author":"BD Leibowitz","year":"2022","unstructured":"Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, et al. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer. 2022;22(1):587.","journal-title":"BMC Cancer"},{"issue":"1","key":"5854_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/0008-5472.CAN-21-2023","volume":"82","author":"HG Kang","year":"2022","unstructured":"Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, et al. Aberrant transcript usage is associated with homologous recombination deficiency and predicts therapeutic response. Cancer Res. 2022;82(1):142\u201354.","journal-title":"Cancer Res"},{"issue":"4","key":"5854_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2017-03-735654","volume":"130","author":"MA Jensen","year":"2017","unstructured":"Jensen MA, Ferretti V, Grossman RL, Staudt LM. The NCI genomic data commons as an engine for precision medicine. Blood. 2017;130(4):453\u20139.","journal-title":"Blood"},{"issue":"10","key":"5854_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113\u201320.","journal-title":"Nat Genet"},{"issue":"1","key":"5854_CR30","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","volume":"10","author":"H Takaya","year":"2020","unstructured":"Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 2020;10(1):2757.","journal-title":"Sci Rep"},{"issue":"10","key":"5854_CR31","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776\u201382.","journal-title":"Br J Cancer"},{"issue":"21","key":"5854_CR32","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","volume":"72","author":"T Popova","year":"2012","unstructured":"Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation. Cancer Res. 2012;72(21):5454\u201362.","journal-title":"Cancer Res"},{"issue":"4","key":"5854_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366\u201375.","journal-title":"Cancer Discov"},{"issue":"12","key":"5854_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","volume":"54","author":"DW Garsed","year":"2022","unstructured":"Garsed DW, Pandey A, Fereday S, Kennedy CJ, Takahashi K, Alsop K, Hamilton PT, Hendley J, Chiew YE, Traficante N, et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat Genet. 2022;54(12):1853\u201364.","journal-title":"Nat Genet"},{"issue":"7","key":"5854_CR35","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"key":"5854_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"issue":"15","key":"5854_CR37","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res"},{"issue":"7553","key":"5854_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489\u201394.","journal-title":"Nature"},{"key":"5854_CR39","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/ncomms4361","volume":"5","author":"G Peng","year":"2014","unstructured":"Peng G, Lin CCJ, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo QX, Siwko S, Hu RZ, et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun. 2014;5:3361.","journal-title":"Nat Commun"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-024-05854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-024-05854-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-024-05854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:02:52Z","timestamp":1720778572000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-024-05854-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5854"],"URL":"https:\/\/doi.org\/10.1186\/s12859-024-05854-y","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no completing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}